Innovacorp’s Early Stage Commercialization Fund (ESCF) helps move Nova Scotia university, college and university-affiliated hospital research to market.
Harbr, a mobile job site reporting app that provides predictive scheduling and intelligence for construction, has closed an oversubscribed Seed round of C$1.75 million. This round brings together notable real-estate and construction executives from across North America, giving Harbr access to major markets in the U.S. and Canada.
Legado Capital (Legado) is pleased to announce the successful closing of the acquisition of Kivuto Solutions Inc. (Kivuto), along with a group of investors, including the lead investor, Roynat Equity Partners. (Innovacorp was a founding investor in Kivuto, then e-Academy.)
Update: CheckIn won Shift Challenge, receiving $20,000 and business guidance to put their idea into action. Paraglide won the audience choice award, receiving $5,000.
We received 26 Shift Challenge submissions. A judging committee selected a shortlist of applicants to move on in the challenge.
Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The software empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions.
University of Manchester Research Finds Densitas’ Breast Density Software Demonstrates a Strong Association with Breast Cancer Risk
Densitas Enters Australian Market with Machine Learning Technology for Breast Health
Densitas Inc. announced today that it has received regulatory clearance for its automated breast density software, DM-Density. DM-Density has received regulatory clearance from the Australian Therapeutic Goods Administration (TGA) and will be available through the EnvoyAI Platform.
A new provincial program will help recent graduates with advanced degrees start their careers with Nova Scotia businesses.
Innovacorp announced an addition to its board of directors today, Feb. 14.
Christopher Googoo, chief operating officer of Ulnooweg Development Group, has been appointed to the board until September 2020.
Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company developing and commercializing anti-infective drugs, announced today it raised an additional $4,339,000 in an oversubscribed private placement financing, bringing the total equity raised since its seed round in March 2016 to $11,816,000.